FBXO33

Across TCGA pan-cancer cohorts, FBXO33 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO33 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher FBXO33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO33 expression acts as an unfavorable survival marker.

CESC, SKCM, and KIRP are the cancer types where FBXO33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	24	view →
SKCM	OS	Median	All	0.230	0.781	.004	19	view →
KIRP	OS	Median	All	0.574	0.903	.005	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO33–CESC (OS)

Open the CESC breakdown →